Search
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalOteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB...
AX200
go.drugbank.com/drugs/DB05093InvestigationalAX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval.
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalThis study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.
AVN-944
go.drugbank.com/drugs/DB05500InvestigationalAVN944 has been associated with cancer cell death in clinical trials. It is being investigated for the treatment of patients with advanced hematologic malignancies.
Rotenone
go.drugbank.com/drugs/DB11457ExperimentalVet approvedRotenone is an isoflavone compound that naturally occurs in the jicama vine plant as well as many Fabaceae plants. It has broad spectrum insecticide and pesticide activity and is also toxic to fish.
Synonyms: (12aS,6aS,2R)-8,9-dimethoxy-2-(1-methylvinyl)-1,2-dihydrochromano[3,4-b]furano [2,3-h]chroman-6-oneCaptodiame
go.drugbank.com/drugs/DB09014ExperimentalCaptodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. … Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.
Metralindole
go.drugbank.com/drugs/DB09306ExperimentalMetralindole, also known as Inkazan, is similar in structure and pharmacology to pirlindole. It functions as a reversible inhibitor of monoamine oxidase A. … In Russia, this drug was investigated for potential antidepressant activity.
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalCelcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.
Psilocybin
go.drugbank.com/drugs/DB11664InvestigationalPsilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.